Skip to main content
Clinical Trials/NCT03680833
NCT03680833UnknownNot Applicable

Sentinel Node Detection in Cervical Cancer

Region Skane2 sites in 1 country226 target enrollmentStarted: June 15, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Enrollment
226
Locations
2
Primary Endpoint
Sentinel node detection in cervical cancer; Sensitivity and negative predictive values for identifying pelvic nodal disease, See detailed study protocol

Study Overview

Brief Summary

Evaluation of sensitivity of Sentinel lymph nodes for detecting nodal metastases in cervical cancer

Detailed Description

Consecutive women with stage 1a2-2a1 cervical cancer scheduled for surgery will be approached for eligibility by defined criteria.

Sentinel nodes will be detected by a combined use of Indocyanine green and Tc99 radiocolloid ( first 75 patients) and for the continuation with either the combined use or the best performing of those tracers.

Technical success rates, adverse events (related study intervention and overall) sensitivity and negative predictive values will be estimated.

An interim analyse will be performed after 34 node positive patients based on the Fleming two stage analyse. The null hypothesis of sensitivity of 85% will be tested against an estimated sensitivity of 95%. At this stage the study may be closed for futility, closed as hull hypothesis is rejected or continued to reach another 28 node positive patients.

As a full pelvic lymphadenectomy will be performed after detection of sentinel nodes patient will act ast their own controls.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Women of age 18 years and older at the time of informed consent.
  • Women with a pathologically proven cervical carcinoma of any histologic subtype, clinically stage 1a2- 2a1 planned for primary surgery
  • Absence of any exclusion criteria

Exclusion Criteria

  • Non consenting patients
  • Ongoing pregnancy
  • Inability to understand written and/or oral study information
  • Who performance status III or more
  • Previous lower limb lymphedema
  • Surgical contraindication to a laparoscopic approach or lymphadenectomy at surgeons discretion.
  • Anesthesiologic contraindication to a laparoscopic approach at the anesthetist's discretion
  • Locally advanced disease or intraabdominal/distant metastases at preoperative CT, MRI or ultrasonography
  • Radiologically suspect pelvic nodal metastatic disease according to the RECIST criteria (>= 1 node with >=16 mm short axis diameter)
  • Allergy to Iodine
  • Patients with a known liver disease
  • Patients with a significant bleeding disorder or mandatory antithrombotic treatment.

Arms & Interventions

prospective cohort study

Other

Prospective cohort study with detection of sentinel lymph nodes followed by a full pelvic lymphadenectomy. Patients will act as their own controls.

The intervention is the detection and removal of sentinel lymph nodes

Intervention: Sentinel node detection in cervical cancer (Procedure)

Outcomes

Primary Outcomes

Sentinel node detection in cervical cancer; Sensitivity and negative predictive values for identifying pelvic nodal disease, See detailed study protocol

Time Frame: 4-5 years

Detection of Sentinel nodes followed by full pelvic lymphadenectomy

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Active, not recruiting
Not Applicable
Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010)SurgeryQuality of LifeCervical Cancer
NCT02642471Sun Yat-sen University1,080
Active, not recruiting
Phase 1
Identification of lymphatic metastasis in patients with parotid gland carcinoma by means of sentinel lymph node biopsy using 68-galium-tilmanocept PET-CT.The IMP will be used for the identification of sentinel lymph node(s) in patients with parotid gland carcinoma.MedDRA version: 21.1Level: LLTClassification code 10026329Term: Malignant neoplasm of parotid glandSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10072873Term: Sentinel lymph node mappingSystem Organ Class: 100000004848MedDRA version: 20.1Level: LLTClassification code 10073554Term: Sentinel node biopsySystem Organ Class: 100000004848
EUCTR2021-003068-28-NLniversity Medical Center Utrecht10
Recruiting
Phase 3
Sentinel lymph node detection of cervical occult lymph node metastases in patients with parotid gland carcinoma by means of sentinel node biopsy using 68-galium-tilmanocept PET-CT.
NL-OMON51066niversitair Medisch Centrum Utrecht10
Unknown
Not Applicable
Sentinel Node Detection in Endometrial Cancer: A Consolidation Study on Detection Rates of Metastatic DiseaseSentinel Lymph NodeEndometrial CancerLymphedema
NCT03838055Region Skane362
Completed
Not Applicable
Sentinel Node and Endometrial CancerEndometrial Neoplasms
NCT00987051Assistance Publique - Hôpitaux de Paris133